Decentralized trial and registry patient-engagement software to generate Real World Evidence for the Life Science Industry.

Peer-Reviewed Journal & Conference Publications

Published Study Results and Data Using EmpiraMed Technology:

1. Kingrey J, Swisher J, Ravichandran A et al. Interim Data from the ADAPT Registry: Patient-Reported Real-World Tolerability and Management of Adverse Events with Oral Treprostinil. Presented at CHEST Annual Meeting 2020. Link to Publication


2. Sahay S, Khan A, Lachant D, et al. Interim Analysis from the ADAPT Registry: Real-World Patient Reported Outcomes Using SF-12 and Emphasis-10 in Patients Receiving Oral Treprostinil. Presented at CHEST Annual Meeting 2021. Link to Publication


3. Lee, S.; et al. “A Prospective Observation Study of Patient Reported Outcomes and Patient Satisfaction With Biologic Treatment for Plaque Psoriasis.” Poster Presentation. wAAD (Winter American Academy of Dermatology Conference), Orlando Florida, March 3-7, 2017.


4. Khatri BO, Morawski J, Chung L, Poole E, Hashemi L, Bury D. “Significant and clinically meaningful health-related quality of life improvements with alemtuzumab in RRMS patients in clinical practice: interim results from a prospective, non-interventional, real-world study (PROMiS).” Poster (P3.2-098) Presentation at 71st American Academy of Neurology (AAN) Annual Meeting, May 4-10, 2019, Philadelphia, PA, USA.


5. Khatri BO, Morawski J, Chung L, Poole E, Hashemi L, Bury D. “Significant and clinically meaningful health-related quality of life improvements with alemtuzumab in RRMS patients in clinical practice: interim results from a prospective, non-interventional, real-world study (PROMiS).” Neurology. April 09, 2019; 92 (15 Supplement) May 7, 2019. Link to Publication


6. Khatri BO, Chung L, Poole E, Hashemi L, Bury D. “Significant improvement in treatment satisfaction among RRMS patients receiving Alemtuzumab in real-world clinical practice in the US: interim results from a prospective, non-interventional, online survey of patient-reported outcomes (PROMiS).” Poster at 71st American Academy of Neurology (AAN) Annual Meeting, May 4-10, 2019, Philadelphia, PA, USA


7. Khatri BO, Chung L, Poole E, Hashemi L, Bury D. “Improved Treatment Satisfaction with Alemtuzumab among RRMS Patients in Clinical Practice: Interim Results from a Prospective, Non-Interventional, Real-World Study (PROMiS).” Poster at Academy of Managed Care Pharmacy (AMCP) Annual Meeting, Mar 25-28, 2019, San Diego, CA, USA


8. Khatri BO, Chung L, Poole E, Hashemi L, Bury D. “Significant and clinically meaningful health-related quality of life improvements with alemtuzumab in RRMS patients in clinical practice: interim results from a prospective, non-interventional, online survey of patient-reported outcomes (PROMiS).” Poster at Academy of Managed Care Pharmacy (AMCP) Annual Meeting, Mar 25-28, 2019, San Diego, CA, USA


9. Khatri BO, Morawski J, Chung L, Poole E, Bury D. “PROMiS (A Prospective, Non-interventional Study in US Patients With Relapsing-remitting Multiple Sclerosis Treated with Alemtuzumab in Routine Clinical Practice): Interim Results on Treatment History and Satisfaction With Alemtuzumab.” Poster at 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), October 10-12, 2018, Berlin, Germany


10. Khatri BO, Morawski J, Chung L, Poole E, Bury D. “A Prospective, Non-interventional Study in US Patients With Relapsing-remitting Multiple Sclerosis Treated With Alemtuzumab in Routine Clinical Practice (PROMiS): Interim Results on Patient Reported Outcomes.” Poster at 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), October 10-12, 2018, Berlin, Germany


11. Morawski J, Cox F, Bury D, Kulkarni P, Thangavelu K. “Patient Reported Treatment Satisfaction and Health-Related Quality of Life in Relapsing-Remitting Multiple Sclerosis Patients Receiving an Oral Disease-Modifying Therapy.” Poster at American Academy of Neurology (AAN) Annual Meeting, April 22–28, 2017, Boston, MA


12. Murthy, Kalyani; et al. “A Pilot Observational Study of Hypoglycemia: Patient Reporting Using a Web-Based Portal Compared to Paper Surveys.” Journal of Diabetes Science and Technology. October, 2017. Link to Publication


13. Murthy, Kalyani; et al. “Web-Portal in T2D.” American Diabetes Association (ADA) 77th Scientific Sessions. Published Abstract. June 9-13, 2017